# Boehringer Ingelheim clinical trials: 2,305 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 2,305 trials with Boehringer Ingelheim as lead sponsor, 62 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Boehringer Ingelheim: 2,305 rows for $103.05, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 6 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 2,305
- Recruiting or not yet: 62
- Read on: November 19, 2026

## Trials

The 25 newest of 2,305, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07940244 | A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity | Boehringer Ingelheim | Phase 1 | Not yet recruiting | Healthy, Obesity | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940244) |
| November 10, 2026 | NCT07929051 | A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Advanced Cancer | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929051) |
| November 9, 2026 | NCT07926334 | A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation | Boehringer Ingelheim | Phase 1 | Not yet recruiting | Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926334) |
| November 9, 2026 | NCT07926321 | A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment | Boehringer Ingelheim | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926321) |
| November 9, 2026 | NCT07926308 | Real-world Outcome of Zongertinib in Japan (J-HERZ) | Boehringer Ingelheim | Observational | Not yet recruiting | Non-small Cell Lung Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926308) |
| November 4, 2026 | NCT07915219 | A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON) | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Bronchiectasis | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915219) |
| October 30, 2026 | NCT07908004 | A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People | Boehringer Ingelheim | Phase 1 | Recruiting | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908004) |
| October 30, 2026 | NCT07907991 | The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Chronic Obstructive Pulmonary Disease | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907991) |
| October 2, 2026 | NCT07855900 | SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose... | Boehringer Ingelheim | Phase 3 | Recruiting | Obesity | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855900) |
| October 1, 2026 | NCT07851103 | A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer | Boehringer Ingelheim | Phase 1 | Recruiting | Advanced Solid Tumour | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851103) |
| September 30, 2026 | NCT07850063 | ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and... | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850063) |
| September 30, 2026 | NCT07850050 | SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have... | Boehringer Ingelheim | Phase 3 | Recruiting | Obesity | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850050) |
| September 29, 2026 | NCT07845630 | A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body | Boehringer Ingelheim | Phase 1 | Recruiting | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845630) |
| September 28, 2026 | NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | Boehringer Ingelheim | Phase 1/2 | Recruiting | Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843940) |
| September 23, 2026 | NCT07837648 | A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in Two Different Ways | Boehringer Ingelheim | Phase 1 | Recruiting | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837648) |
| August 27, 2026 | NCT07789028 | A Study in Healthy People to Test How Zongertinib is Taken up in the Body When Given as Tablets Made by Two Different Manufacturers With or... | Boehringer Ingelheim | Phase 1 | Recruiting | Healthy | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789028) |
| August 27, 2026 | NCT07789015 | A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Idiopathic Inflammatory Myopathies | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789015) |
| August 24, 2026 | NCT07781631 | A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the Blood | Boehringer Ingelheim | Phase 1 | Recruiting | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781631) |
| August 19, 2026 | NCT07774325 | A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood | Boehringer Ingelheim | Phase 1 | Active not recruiting | Healthy | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774325) |
| August 17, 2026 | NCT07768813 | A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women... | Boehringer Ingelheim | Phase 1 | Active not recruiting | Healthy, Obesity | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768813) |
| August 12, 2026 | NCT07760246 | A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart | Boehringer Ingelheim | Phase 1 | Active not recruiting | Healthy | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760246) |
| August 10, 2026 | NCT07754474 | A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity | Boehringer Ingelheim | Phase 1 | Recruiting | Overweight, Obesity | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754474) |
| August 10, 2026 | NCT07754461 | A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar | Boehringer Ingelheim | Phase 3 | Recruiting | Type 2 Diabetes | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754461) |
| August 4, 2026 | NCT07744152 | A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours) | Boehringer Ingelheim | Phase 1 | Recruiting | Solid Tumours | 137 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744152) |
| August 4, 2026 | NCT07743996 | Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis... | Boehringer Ingelheim | Observational | Completed | Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743996) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 1,065 |
| Phase 1/2 | 15 |
| Phase 2 | 295 |
| Phase 2/3 | 13 |
| Phase 3 | 393 |
| Phase 4 | 126 |
| Not applicable | 23 |
| Observational | 374 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 2,004 |
| Terminated | 155 |
| Recruiting | 51 |
| Active not recruiting | 37 |
| Withdrawn | 31 |
| Not yet recruiting | 11 |
| Approved for marketing | 8 |
| Suspended | 4 |
| No longer available | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pulmonary Disease, Chronic Obstructive | 236 |
| Diabetes Mellitus, Type 2 | 130 |
| Hypertension | 122 |
| HIV Infections | 67 |
| Carcinoma, Non-Small-Cell Lung | 67 |
| Asthma | 62 |
| Neoplasms | 61 |
| Atrial Fibrillation | 45 |
| Parkinson Disease | 42 |
| Idiopathic Pulmonary Fibrosis | 36 |
| Obesity | 32 |
| Stroke | 23 |
| Lung Diseases, Interstitial | 23 |
| Psoriasis | 20 |
| Restless Legs Syndrome | 20 |
| Arthritis, Rheumatoid | 19 |
| Prostatic Hyperplasia | 18 |
| Hepatitis C, Chronic | 18 |
| Venous Thromboembolism | 16 |
| Breast Neoplasms | 16 |
| Osteoarthritis | 15 |
| Colorectal Neoplasms | 14 |
| Head and Neck Neoplasms | 13 |
| Heart Failure | 13 |
| Renal Insufficiency, Chronic | 13 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water purification companies in the United States](https://specstream.ai/data/businesses/water-purification-companies/united-states)
- [Ceiling and roofing repair and companies in the United States](https://specstream.ai/data/businesses/ceiling-and-roofing-repair-and-companies/united-states)
- [Gastropubs in the United States](https://specstream.ai/data/businesses/gastropubs/united-states)
- [Neurology practices in the United States](https://specstream.ai/data/businesses/neurology-practices/united-states)
- [Spring suppliers in the United States](https://specstream.ai/data/businesses/spring-suppliers/united-states)
- [B2B newspaper advertising companies in the United States](https://specstream.ai/data/businesses/b2b-newspaper-advertising-companies/united-states)
